ARPA-H announced it will spend up to $160 million to accelerate custom gene editing treatments for rare diseases under the THRIVE program. The agency will back seven different teams, with a goal that each begins clinical trials by year three of the effort, aiming to shorten the path from design to patient testing. The initiative emphasizes rapid progression for bespoke therapies, reflecting ongoing competition to prove scalable gene-editing delivery and efficacy across heterogeneous disease genetics. Teams will each pursue distinct condition groups affecting different organ systems. For the biotech ecosystem, THRIVE signals that non-dilutive, government-backed funding is actively targeting operational bottlenecks in custom editing programs—potentially reshaping what sponsors prioritize for proof-of-concept and early clinical scaling.